Skip to main content

Table 3 Summary of the antimicrobial susceptibility testing results of AXDX, after adjudication

From: Evaluation of the impact of the Accelerate Pheno™ system on time to result for differing antimicrobial stewardship intervention models in patients with gram-negative bloodstream infections

AntimicrobialEACAVMEMEmESIR
No. results/total%No. results/total%
Amikacin82/82100%84/84100%0007707
Ampicillin-Sulbactam57/6291.9%48/6277.4%001430725
Aztreonam71/7495.9%72/7596%00354120
Cefepime79/8296.3%79/8395.2%00460221
Ceftriaxone74/74100%71/7594.7%00452122
Ciprofloxacin79/8395.2%84/84100%00048036
Ertapenem72/7398.6%72/7398.6%0016508
Gentamicin80/8396.4%84/84100%00066018
Meropenem79/8395.2%83/8597.6%00270114
Piperacillin-Tazobactam63/6892.6%70/7593.3%00555317
Tobramycin78/8394%77/8491.7%00762517
Overall814/84796.1%824/86495.4%004063920205
  1. EA essential agreement, CA categorical agreement, VME very major error, ME major error, mE minor error, S susceptible, I intermediate, R resistant